Drug intelligence / Profile preview

BLT-1

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

BLT-1 (Block Lipid Transport 1) is a potent, small-molecule inhibitor of Scavenger Receptor Class B Type 1 (SR-B1). SR-B1 is a multi-functional membrane receptor that facilitates the selective uptake of cholesteryl esters from high-density lipoprotein (HDL) into cells. In the context of oncology, BLT-1 is being investigated for its ability to disrupt lipid metabolism in cancer cells, particularly triple-negative breast cancer (TNBC), where SR-B1 is often overexpressed to meet high metabolic demands. Preclinical studies have shown that the efficacy of BLT-1 is influenced by extracellular glucose levels and specific genetic polymorphisms in the SR-B1 gene (such as rs2293440), highlighting its potential role in personalized metabolic-targeted cancer therapy.

Other names: Block lipid transport 1

Targets

SCARB1 (Scavenger receptor class B member 1)

Beyond the preview

Go deeper on BLT-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BLT-1.

Explore the full profile